NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/21/2024
Back to search
Official data from USPTO
NOVOCOL PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NOVOCOL PHARMA
ST13
US500000088221050Class
5, 10, 35, 40, 42, 45
Filing
88221050
Registration
7390115
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
62
Latest update
04/03/2025
Trademark type
Word
Nice classes
5, 10, 35, 40, 42, 45
Filing date
12/07/2018
Registration date
05/21/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/21/2024
Last transaction
04/03/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
99
Owner location
Saint-Maur-des fosses, FR
Examiner
FATHY, DOMINIC
Law office
L40
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Septodont Holding SAS
Representatives
JASON J. MAZUR ARENTFOX SCHIFF LLP
Technical classification
Nice Classes
Class 5Class 10Class 35Class 40Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationsacne medicationallergy medicationantacidsanthelminticsantiarrhythmicsantibiotic creams and ointmentsantibioticsanticoagulantsanticonvulsantsantidepressantsantiemeticsantiflatulantsantihistaminesantihypertensives anti-infectivesanti-inflammatoriesantiparasitesantiviralsburn relief medicationcalcium channel blockerscentral nervous system depressantscentral nervous system stimulantscough treatment medicationdiarrhea medicationfungal medicationsgastro-intestinal pharmaceutical preparationsglaucoma agentshydrocortisonehypnotic agentssedativespain relief medicationtopical and injectable pharmaceutical preparations for dentalendodontic and periodontal disorders; anti-epileptic pharmaceutical preparations; bismuth preparations for pharmaceutical use; bromine for pharmaceutical purposes; cardiovascular pharmaceutical preparations; frostbite salve for pharmaceutical purposes; guaiacol for pharmaceutical purposes; intravenous fluids used for rehydrationnutrition and the delivery of pharmaceutical preparations; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; injectable pharmaceutical contraceptives; pharmaceutical anti-allergic preparations and substances; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical hormonal preparationscorticosteroidshormone replacement therapy preparationsoral contraceptivesthyroid hormone preparations; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the relief of pain; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of bacterial skin infectionsfungal skin infectionsviral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of degenerative nerve diseases and disordersAlzheimer's diseaseParkinson's diseaseHuntington's disease and multiple sclerosis; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diseasesdisorders and infections of the endocrine systemgrowth and thyroid disorders; pharmaceutical preparations for the treatment of diseasesdisorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseasesdisorders and infectionsinfertilitysexually transmitted diseasesincontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseasesurological diseasesinfertilitysexually transmitted diseasesinflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseasesautoimmune diseasesimmunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseasesrespiratory infectionseye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseasesinflammatory bowel diseasesinflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disordersgoutosteoarthritismuscular dystrophyanemia; pharmaceutical preparations for the treatment of metabolic disordersbulimia nervosaanorexiahypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseasesAlzheimer'sHuntington's Diseasecerebral palsy; pharmaceutical preparations for the treatment of neurological disordersbrain injuryspinal cord injuryseizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorderscerebrovascular accident (stroke)Parkinson's diseasemultiple sclerosismyasthenia gravisHuntington's disease; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment of physical and psychological addictionsgambling addictioneating disorders and addictionsnicotine addictionInternet addictiondrug addiction; pharmaceutical preparations for the treatment of psychiatric and other brain diseases and disordersanxietymood disordersschizophreniacognitive and bipolar disordersepilepsyAlzheimer'scerebral palsyParkinson's diseasemultiple sclerosis; pharmaceutical preparations for the treatment of psychiatric diseasesmood disordersanxiety disorderscognitive disordersschizophrenia; pharmaceutical preparations for the treatment of respiratory diseasesdisorders and infections; pharmaceutical preparations for the treatment of skin irritationsbee stingssunburnrashessorescornscallusesacne; pharmaceutical preparations for the treatment of smoking cessation; pharmaceutical preparations for the treatment of the central nervous systemcentral nervous system infectionsbrain diseasescentral nervous system movement disordersocular motility disordersspinal cord diseases; pharmaceutical preparations for the treatment of the central nervous systemencephalitisepilepsyAlzheimer'scerebral palsyParkinson's disease; pharmaceutical preparations for the treatment of the diseasesdisorders and infections of the central nervous systembrainmovementocular motility and spinal cord diseases; pharmaceutical preparations for the treatment of the musculoskeletal systemconnective tissue diseasesbone diseasesspinal diseasesback painfracturessprainscartilage injuries; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of varicose veins; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for the treatment of viral diseasesherpeshepatitisAcquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating dandruff; pharmaceutical preparations for use in dermatologydermatitisskin pigmentation diseasessexually transmitted diseases; pharmaceutical preparations for use in discouraging the smoking habit; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for use in ocular disorders; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for wounds; pharmaceutical preparations against dry skin caused by pregnancy; pharmaceutical preparations for hydrating the skin during pregnancy; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for treating respiratory diseases; pharmaceutical solutions used in dialysis; radioactive pharmaceutical preparations for in vivo diagnostic or therapeutic use; sunburn preparations for pharmaceutical purposes; synthetic peptides for the treatment of all of the foregoing diseases and conditions; disinfection systemsall-purpose disinfectants; none of the foregoing for the treatment of cancer or oncological diseases and disorders
Class 10
Drug delivery systemsneedlessyringesnasal spray bottlesinjection devicesoral and nasal inhalation devicespatch pumpsanesthetic delivery apparatus for medical purposesbut not for use in the fields of diabetes and obesity; none of the foregoing for the treatment of cancer or oncological diseases and disorders
Class 35
Business consulting services relating to pharmaceutical manufacturingclinical evaluation and testingregulatory registrationstability studiesmethod developmentformal stabilityregistration batches and commercial production; none of the foregoing for the treatment of cancer or oncological diseases and disorders
Class 40
Contract manufacturing of clinical batches of pharmaceuticals; Consulting services relating to pharmaceutical manufacturingbatch biological treatment batchespharmaceutical manufacturing; custom manufacture of pharmaceuticalsthe formulation of new dosage forms and the reformulation of existing drug products; none of the foregoing for the treatment of cancer or oncological diseases and disorders
Class 42
Consulting services relating to the clinical testinginspectionresearch of pharmaceuticals; Consulting services relating to conducting pharmaceutical stability studies and formal stability studies; Consulting services relating to the development of chemical production methods; Consulting services relating to registration batch research and commercial pharmaceutical products development; Pharmaceutical drug development servicesthe formulation of new dosage forms and the reformulation of existing drug products; none of the foregoing for the treatment of cancer or oncological diseases and disorders
Class 45
Consulting services to assist companies with obtaining regulatory compliance and licenses for pharmaceuticals and medical devices; Consulting services relating to pharmaceuticals relating to regulatory compliance in the field of pharmaceuticalsregulatory registration; none of the foregoing for the treatment of cancer or oncological diseases and disorders
Publications
History of USPTO decisions and trademark events.
62 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/21/2024
TMBN
TTAB RELEASE CASE TO TRADEMARKS
04/16/2024
OP.T
OPPOSITION TERMINATED NO. 999999
04/16/2024
OP.D
OPPOSITION DISMISSED NO. 999999
04/16/2024
OP.I
OPPOSITION INSTITUTED NO. 999999
10/04/2023
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
06/26/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/06/2023
PUBO
PUBLISHED FOR OPPOSITION
06/06/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/17/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/28/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/26/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/26/2023
ALIE
ASSIGNED TO LIE
04/25/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
04/18/2023
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
01/20/2023
GNSI
INQUIRY TO SUSPENSION E-MAILED
01/20/2023
CNSI
SUSPENSION INQUIRY WRITTEN
01/20/2023
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
01/18/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/23/2022
GNSL
LETTER OF SUSPENSION E-MAILED
05/23/2022
CNSL
SUSPENSION LETTER WRITTEN
05/23/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/18/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/18/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
05/17/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/01/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
03/01/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/01/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/01/2022
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
11/23/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
11/23/2021
CNSI
SUSPENSION INQUIRY WRITTEN
11/23/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
11/18/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/17/2021
GNSL
LETTER OF SUSPENSION E-MAILED
05/17/2021
CNSL
SUSPENSION LETTER WRITTEN
05/17/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/17/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/17/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
05/14/2021
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
11/30/2020
GNSI
INQUIRY TO SUSPENSION E-MAILED
11/30/2020
CNSI
SUSPENSION INQUIRY WRITTEN
11/30/2020
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
11/13/2020
ALIE
ASSIGNED TO LIE
11/02/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
02/28/2020
GNSL
LETTER OF SUSPENSION E-MAILED
02/28/2020
CNSL
SUSPENSION LETTER WRITTEN
02/28/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/11/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/11/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
02/11/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
09/03/2019
GNSL
LETTER OF SUSPENSION E-MAILED
09/03/2019
CNSL
SUSPENSION LETTER WRITTEN
09/03/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/13/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/13/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/13/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/13/2019
GNRT
NON-FINAL ACTION E-MAILED
03/13/2019
CNRT
NON-FINAL ACTION WRITTEN
03/13/2019
DOCK
ASSIGNED TO EXAMINER
03/07/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/30/2018
NWAP
NEW APPLICATION ENTERED
12/11/2018
Continuous trademark protection
Get notified about every new filing that threatens NOVOCOL PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.